https://doi.org/10.4081/monaldi.2013.26
Roflumilast: the fourth Mousquetaire in COPD pharmacological treatment
Submitted: August 18, 2015
Accepted: August 18, 2015
Published: August 19, 2015
Accepted: August 18, 2015
Abstract Views: 927
PDF: 589
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
How to Cite
Balbi, Bruno. 2015. “Roflumilast: The Fourth Mousquetaire in COPD Pharmacological Treatment”. Monaldi Archives for Chest Disease 79 (3-4). https://doi.org/10.4081/monaldi.2013.26.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Guido Levi, Chiara Rocchetti, Roberto Magri, Silvia Uccelli, Damiano Bottone, Federico Quadri, Mauro Novali, Alessandro D. Santin, Michela Bezzi, Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma , Monaldi Archives for Chest Disease: Vol. 91 No. 4 (2021)
- Lawrence Paelet, Jonathan Raskin, Richard ZuWallack, Potential downside issues with telemedicine for individuals with chronic respiratory diseases , Monaldi Archives for Chest Disease: Vol. 92 No. 4 (2022)
You may also start an advanced similarity search for this article.
